ThedaCare Advises Careful Discontinuation of Weight Loss Drugs
ThedaCare is urging individuals who are stopping the use of GLP-1 medications, commonly prescribed for weight loss, to do so gradually to avoid rapid weight regain.
These drugs, including Ozempic and Wegovy, were originally developed to manage blood sugar levels in people with type 2 diabetes but have gained popularity for their appetite-suppressing and digestion-slowing effects, leading to weight loss. A recent trend shows many Wisconsin residents use these medications for an average of seven months before discontinuing or reducing dosage. The increasing use of these drugs has sparked debate about long-term health impacts and accessibility.
Dr. Benjamin Duffy, an obesity medicine specialist and director of ThedaCare Weight Wellness Solutions, emphasized the importance of a structured weaning process. “We try to help people taper off their treatment dose over about two months so that as their appetite slowly increases, so does their metabolism,” he said. Individuals considering starting a weight loss journey can find resources and support at ThedaCare.org.
Rapidly stopping these medications can lead to a quick return of appetite and potential weight gain, highlighting the need for a comprehensive approach to weight management that includes lifestyle changes. For more information on GLP-1 receptor agonists, visit the Mayo Clinic website.
ThedaCare officials recommend consulting with a healthcare professional to develop a personalized tapering plan.
